NCT04880447View on ClinicalTrials.gov

Special Investigation of COMIRNATY in the Population With Underlying Diseases

CompletedOBSERVATIONAL

Enrollment

1,075

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

April 14, 2022

Study Completion Date

April 14, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

BNT162b2

COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.

Trial Locations (1)

1518589

Pfizer Local County, Tokyo